February 27, 2018
KEY POINTS ObsEva’s oral drug, nolasiban demonstrated ongoing pregnancy benefit in women undergoing IVF or other assisted reproductive technology (ART) ...
Categories: NEWLY PUBLISHED, News from Europe
Access articles & resources worth up to US $4, 000 per month.
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
Top Companies Leading the Rare Disease Drug Discovery
Liquid Biopsy: An Industrial Review
Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)
Billion Dollars Healthcare Startups (2018)
7 New Ideas to Start a Healthcare Business in India (2018)
Pharma Patents: Can India Reward Incremental Innovation?